company background image
ENZ logo

Enzo Biochem NYSE:ENZ Stock Report

Last Price

US$1.27

Market Cap

US$65.1m

7D

5.0%

1Y

-46.6%

Updated

28 Mar, 2024

Data

Company Financials

ENZ Stock Overview

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide.

ENZ fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Enzo Biochem, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Enzo Biochem
Historical stock prices
Current Share PriceUS$1.27
52 Week HighUS$2.74
52 Week LowUS$1.16
Beta0.75
1 Month Change-5.22%
3 Month Change-8.63%
1 Year Change-46.64%
3 Year Change-64.33%
5 Year Change-56.80%
Change since IPO-93.14%

Recent News & Updates

Enzo Biochem: Cleaned Up And Cash-Rich But Unloved

Oct 26

Recent updates

Enzo Biochem: Cleaned Up And Cash-Rich But Unloved

Oct 26

Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?

May 18
Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Jan 03
Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Enzo Biochem Non-GAAP EPS of -$0.18, revenue of $18.28M

Dec 12

Enzo Biochem appoints Patricia Eckert as interim CFO

Oct 20

Enzo Biochem Non-GAAP EPS of -$0.17, revenue of $20.28M

Oct 14

Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Oct 04
Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Enzo Biochem: Activist Pressure Could Finally Lead To A Company Sale

Jun 27

Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?

May 03
Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Dec 17
Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?

Aug 24
Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?

Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Mar 01
Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?

Feb 03
Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?

If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%

Jan 08
If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%

Enzo Biochem nabs expanded EUA nod for testing of COVID samples

Jan 04

Enzo Biochem: Betting On The Activists Now

Dec 16

Here's What We Think About Enzo Biochem's (NYSE:ENZ) CEO Pay

Dec 13
Here's What We Think About Enzo Biochem's (NYSE:ENZ) CEO Pay

Shareholder Returns

ENZUS HealthcareUS Market
7D5.0%0.6%0.4%
1Y-46.6%9.5%28.8%

Return vs Industry: ENZ underperformed the US Healthcare industry which returned 9.5% over the past year.

Return vs Market: ENZ underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is ENZ's price volatile compared to industry and market?
ENZ volatility
ENZ Average Weekly Movement5.1%
Healthcare Industry Average Movement7.3%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: ENZ has not had significant price volatility in the past 3 months.

Volatility Over Time: ENZ's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1976185Kara Cannonhttps://www.enzo.com

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents.

Enzo Biochem, Inc. Fundamentals Summary

How do Enzo Biochem's earnings and revenue compare to its market cap?
ENZ fundamental statistics
Market capUS$65.06m
Earnings (TTM)-US$23.31m
Revenue (TTM)US$32.80m

2.0x

P/S Ratio

-2.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ENZ income statement (TTM)
RevenueUS$32.80m
Cost of RevenueUS$18.97m
Gross ProfitUS$13.83m
Other ExpensesUS$37.15m
Earnings-US$23.31m

Last Reported Earnings

Jan 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.46
Gross Margin42.17%
Net Profit Margin-71.08%
Debt/Equity Ratio5.0%

How did ENZ perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.